The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer
Official Title: Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study
Study ID: NCT00537173
Brief Summary: This trial provides a unique opportunity in that it combines genomic, proteomic and pharmacogenomic assessments in patients receiving chemotherapy for advanced breast cancer. To date no other trials have analyzed gene and protein expression at the same time points in the same patient, combined with clinical outcome. Similar to previous attempts to predict response based on expression of a single gene or protein, we expect that neither genomic or proteomic profiling alone will be sufficient to optimize therapy. Rather, we expect an iterative process that combines information gleaned from both platforms, modified to avoid toxicity based on pharmacogenomics.
Detailed Description: OUTLINE: This is a multi-center study. Sample Collection: * Core biopsy * Blood sample 28-day Cycle Treatment Regimen: * Paclitaxel 90 mg/m2 IV D1, 8, and 15 * Avastin 10 mg/kg IV D1 and 15 ECOG Performance Status of 0 or 1 Life Expectancy: Not specified Hematopoietic: * Platelet count \> 100,000/mm³ * Absolute neutrophil count \> 1200/mm³ * PTT \< 1.5 x upper limit of normal * INR \< 1.5 x upper limit of normal Hepatic: * Total bilirubin \< 1.5 mg/dL * SGOT (AST) \< 2 x upper limit of normal Renal: Not specified Cardiovascular: * Clinically significant cardiovascular or cerebrovascular disease including prior myocardial infarction (within 6 months prior to study entry), unstable angina, Grade II or greater peripheral vascular disease, New York Heart Association (NYHA) Grade II or greater congestive heart failure, hypertensive crises, hypertensive encephalopathy or uncontrolled hypertension (SBP\>150, DBP\>100).
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Cancer Care Center of Southern Indiana, Bloomington, Indiana, United States
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
Horizon Oncology Center, Lafayette, Indiana, United States
Baylor College of Medicine - Methodist Breast Center, Houston, Texas, United States
Name: George Sledge, M.D.
Affiliation: Hoosier Oncology Group, Inc.
Role: PRINCIPAL_INVESTIGATOR